Interfering with S100B-effector protein interactions for cancer therapy

Area of Science:

• Biochemistry and Molecular Biology
• Oncology
• Drug Discovery

Background:

• S100 calcium-binding protein B (S100B) is frequently overexpressed in malignant tumors.
• S100B influences cancer cell proliferation and metabolism through molecular interactions.
• Targeting S100B-effector protein interactions presents a promising therapeutic strategy for cancer treatment.

Purpose of the Study:

• To review the discovery of S100B-effector protein interaction inhibitors using virtual screening (VS).
• To identify and discuss novel S100B-effector protein targets for in silico drug discovery.
• To highlight the potential of targeting alternative S100B interactions beyond the S100B-p53 pathway.

Main Methods:

• Literature review of virtual screening studies focused on S100B inhibitors.
• Analysis of known S100B-effector protein interactions relevant to cancer.
• In silico approaches for identifying and validating new drug targets.

Main Results:

• Virtual screening has identified some S100B inhibitors, primarily targeting the S100B-p53 interaction.
• There is a significant unmet need and opportunity for discovering modulators of other S100B-effector protein interactions.
• Several S100B-effector protein interactions are potential targets for computational drug discovery.

Conclusions:

• Developing inhibitors for diverse S100B-effector protein interactions is crucial for advancing cancer therapy.
• Virtual screening and in silico analysis are valuable tools for discovering novel S100B-targeted cancer drugs.
• Exploring new S100B targets beyond p53 can lead to more effective treatments for various malignant tumors.